109906
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
罕见的成人隐睾症源发的巨大纯卵黄囊瘤
Authors Wu H, Zhang Y, Zheng W, Bao H, Fu Y, Su Q
Received 18 July 2025
Accepted for publication 24 October 2025
Published 11 November 2025 Volume 2025:17 Pages 2719—2727
DOI https://doi.org/10.2147/CMAR.S554749
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Chien-Feng Li
Hengjiang Wu,1,* Yu Zhang,2,* Wei Zheng,1 Huayu Bao,1 Yuandi Fu,1 Qijian Su2
1Department of Urology, The First People’s Hospital of Qinzhou, Qinzhou, Guangxi Zhuang Autonomous Region, People’s Republic of China; 2Department of Scientific Research, The First People’s Hospital of Qinzhou, Qinzhou, Guangxi Zhuang Autonomous Region, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Qijian Su, Department of Scientific Research, The First People’s Hospital of Qinzhou, Qinzhou, Guangxi Zhuang Autonomous Region, People’s Republic of China, Email agansue@163.com
Abstract: Cryptorchidism is a well-established risk factor for testicular cancer. Among adult male patients, pure testicular yolk sac tumors (YSTs) are rare, and those arising from cryptorchidism in adult males are even less common. We report a case of a 35-year-old male with a giant YST originating from cryptorchidism, with no distant metastasis detected preoperatively. The initial treatment plan was radical orchiectomy combined with postoperative chemotherapy for curative intent, but direct surgery was extremely challenging due to the large tumor size. Therefore, we attempted neoadjuvant chemotherapy to facilitate surgical resection. To our knowledge, there are relatively few reports on the use of neoadjuvant chemotherapy to reduce tumor burden prior to testicular tumor resection. The patient received four cycles of neoadjuvant chemotherapy before surgery, after which the tumor volume decreased, and the levels of alpha-fetoprotein (AFP) and lactate dehydrogenase (LDH) also dropped. Unfortunately, Liver metastases were detected during the reexamination on the 28th post-operative day, and lung metastases were identified in another reexamination on the 85th post-operative day. Regrettably, the patient refused further treatment and discontinued it, and we eventually lost follow-up. Post-pubertal YSTs are highly aggressive, and early detection and intervention are crucial for patients suspected of having cryptorchidism. Neoadjuvant chemotherapy can be considered as an adjuvant therapeutic strategy for reducing tumor burden in testicular tumors.
Keywords: cryptorchidism, yolk sac tumor, testicular cancer, neoadjuvant chemotherapy
1Department of Urology, The First People’s Hospital of Qinzhou, Qinzhou, Guangxi Zhuang Autonomous Region, People’s Republic of China; 2Department of Scientific Research, The First People’s Hospital of Qinzhou, Qinzhou, Guangxi Zhuang Autonomous Region, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Qijian Su, Department of Scientific Research, The First People’s Hospital of Qinzhou, Qinzhou, Guangxi Zhuang Autonomous Region, People’s Republic of China, Email agansue@163.com
Abstract: Cryptorchidism is a well-established risk factor for testicular cancer. Among adult male patients, pure testicular yolk sac tumors (YSTs) are rare, and those arising from cryptorchidism in adult males are even less common. We report a case of a 35-year-old male with a giant YST originating from cryptorchidism, with no distant metastasis detected preoperatively. The initial treatment plan was radical orchiectomy combined with postoperative chemotherapy for curative intent, but direct surgery was extremely challenging due to the large tumor size. Therefore, we attempted neoadjuvant chemotherapy to facilitate surgical resection. To our knowledge, there are relatively few reports on the use of neoadjuvant chemotherapy to reduce tumor burden prior to testicular tumor resection. The patient received four cycles of neoadjuvant chemotherapy before surgery, after which the tumor volume decreased, and the levels of alpha-fetoprotein (AFP) and lactate dehydrogenase (LDH) also dropped. Unfortunately, Liver metastases were detected during the reexamination on the 28th post-operative day, and lung metastases were identified in another reexamination on the 85th post-operative day. Regrettably, the patient refused further treatment and discontinued it, and we eventually lost follow-up. Post-pubertal YSTs are highly aggressive, and early detection and intervention are crucial for patients suspected of having cryptorchidism. Neoadjuvant chemotherapy can be considered as an adjuvant therapeutic strategy for reducing tumor burden in testicular tumors.
Keywords: cryptorchidism, yolk sac tumor, testicular cancer, neoadjuvant chemotherapy